Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.44 |
| ▸ | TDP2 | O95551 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15935912 | 0.81 | ADRA2A (0.41) | CYP19A1CALCRLMAPTPARP1ALDH1A1 | |
| SCHEMBL260991 | 0.80 | CA9 (0.39) | CA9CYP19A1TDP2CASP1CASP7 | |
| SCHEMBL11073635 | 0.79 | TDP2 (0.47) | TDP2CALCRLPARP1 | |
| SCHEMBL259592 | 0.77 | CRBN (0.44) | TDP2CASP7CALCRLMAPTCRBN | |
| SCHEMBL13015179 | 0.76 | KIF11 (0.36) | CYP19A1TDP2HSD17B10CALCRLMAPT | |
| SCHEMBL13062459 | 0.76 | PARP1 (0.40) | CYP19A1CALCRLMAPTLMNAKDM4E | |
| SCHEMBL11072700 | 0.76 | OTUD7B (0.48) | TDP2GAAALDH1A1 | |
| SCHEMBL380001 | 0.75 | CALCRL (0.41) | CA9TDP2CASP1CASP7HSD17B10 | |
| SCHEMBL260824 | 0.74 | CRBN (0.53) | CA9TDP2MAPTLMNACA12 | |
| SCHEMBL11095671 | 0.74 | HTT (0.41) | CYP19A1CALCRLKMT2ACRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134342-B1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-01-30 | — | — | EP | disclosed |
| EP-2134342-B1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-01-30 | — | — | EP | disclosed |
| EP-1791843-B1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-1791843-B1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8148390-B2 | Monocyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme, Corp. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148390-B2 | Monocyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme, Corp. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148390-B2 | Monocyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme, Corp. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8133891-B2 | Tricyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133891-B2 | Tricyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133891-B2 | Tricyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20080214511-A1 | Tricyclic Anilide Spirolactam Cgrp Receptor Antagonists | MERCK & CO., INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080096878-A1 | CGRP (Calcitonin Gene-Related Peptide); migraine and cluster headaches; 2-(5-Bromo-1'1'-dioxido-2-oxo-2',3',5',6'-tetrahydrospiro[indole-3,4'-thiopyran]-1 (2H)-yl)-N-(2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)acetamide for example; use with other drugs | MERCK SHARP & DOHME LLC | 2008-04-24 | — | — | US | disclosed |
| US-20080096878-A1 | CGRP (Calcitonin Gene-Related Peptide); migraine and cluster headaches; 2-(5-Bromo-1'1'-dioxido-2-oxo-2',3',5',6'-tetrahydrospiro[indole-3,4'-thiopyran]-1 (2H)-yl)-N-(2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)acetamide for example; use with other drugs | MERCK SHARP & DOHME LLC | 2008-04-24 | — | — | US | disclosed |
| US-20080096878-A1 | CGRP (Calcitonin Gene-Related Peptide); migraine and cluster headaches; 2-(5-Bromo-1'1'-dioxido-2-oxo-2',3',5',6'-tetrahydrospiro[indole-3,4'-thiopyran]-1 (2H)-yl)-N-(2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)acetamide for example; use with other drugs | MERCK SHARP & DOHME LLC | 2008-04-24 | — | — | US | disclosed |
| US-20080004304-A1 | Aryl Spirolactam Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-01-03 | — | — | US | disclosed |
| US-20080004304-A1 | Aryl Spirolactam Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-01-03 | — | — | US | disclosed |
| US-20080004304-A1 | Aryl Spirolactam Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-01-03 | — | — | US | disclosed |
| WO-2007061677-A2 | SPIROLACTAM ARYL CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061692-A2 | SPIROLACTAM TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061696-A2 | SPIROLACTAM BICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214511-A1 | Tricyclic Anilide Spirolactam Cgrp Receptor Antagonists | BDKRB1, CALCRL, BDKRB2 | CA9 1937/4885CYP19A1 2328/4885TDP2 3280/4885 |
| US-20080096878-A1 | CGRP (Calcitonin Gene-Related Peptide); migraine and cluster headaches; 2-(5-Bromo-1'1'-dioxido-2-oxo-2',3',5',6'-tetrahydrospiro[indole-3,4'-thiopyran]-1 (2H)-yl)-N-(2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)acetamide for example; use with other drugs | CALCB, BDKRB2, BDKRB1 | CA9 2287/4885CYP19A1 1684/4885TDP2 1694/4885 |
| US-20080004304-A1 | Aryl Spirolactam Cgrp Receptor Antagonists | BDKRB1, BDKRB2, CALCRL | CA9 2331/4885CYP19A1 1300/4885TDP2 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.